References
- Chelly J, Desguerre I. Progressive muscular dystrophies. Handb. Clin. Neurol. 113, 1343–66 (2013).
- Pane M, Messina S, Vasco G et al. Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency. Neuromuscul. Disord. 22, 685–689 (2012).
- Scionti I, Greco F, Ricci G et al. Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. 90, 628–635 (2012).
- Keren R, Zaoutis TE, Bridges CB et al. Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. JAMA. 294, 2188–2194 (2005).
- Esposito S, Cecinati V, Scicchitano B et al. Impact of influenza-like illness and effectiveness of influenza vaccination in oncohematological children who have completed cancer therapy. Vaccine 28, 1558–1565 (2010).
- Menni F, Chiarelli G, Sabatini C, Principi N, Esposito S. Vaccination in children with inborn errors of metabolism. Vaccine 30, 7161–7164 (2012).
- Esposito S, Principi N. Differences in vaccinations in European Union. Hum Vaccin. 4, 313–315 (2008).
- Csuka D, Czirják L, Hóbor R et al. Effective humoral immunity against diphtheria and tetanus in patients with systemic lupus erythematosus or myasthenia gravis. Mol. Immunol. 54(3–4), 453–456 (2013).
- Esposito S, Cecinati V, Brescia L, Principi N. Vaccinations in children with cancer. Vaccine 28, 3278–3284 (2010).
- Dell' Era L, Esposito S, Corona F, Principi N. Vaccination of children and adolescents with rheumatic diseases. Rheumatology (Oxf.) 50, 1358–1365 (2011).
- Marin M, Broder KR, Temte JL et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59(RR–3), 1–12 (2010).
- Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012–13 influenza season. MMWR Morb. Mortal Wkly. Rep. 2012 61, 613–618 (2012).
- Esposito S, Tagliabue C, Tagliaferri L, Semino M, Longo MR, Principi N. Preventing influenza in younger children. Clin. Microbiol. Infect. 18(Suppl. 5), 42–49 (2012).
- Esposito S, Principi N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr. Opin. Infect. Dis. 22, 244–249 (2009).
- Marchisio P, Baggi E, Bianchini S, Principi N, Esposito S. Clinical and socioeconomic impact of pediatric seasonal and pandemic influenza. Hum. Vaccin. Immunother. 8, 17–20 (2012).
- Esposito S, Montinaro V, Bosis S, Tagliabue C, Baggi E, Principi N. Recommendations for the use of influenza vaccine in pediatrics. Hum. Vaccin. Immunother. 8, 102–106 (2012).
- Principi N, Esposito S, Marchisio P. Present and future of influenza prevention in pediatrics. Expert Opin. Biol. Ther. 11, 641–653 (2011).
- Esposito S, Pelucchi C, Tel F et al. Factors conditioning effectiveness of a reminder/recall system to improve influenza vaccination in asthmatic children. Vaccine 27, 633–635 (2009).
- Cecinati V, Esposito S, Scicchitano B et al. Effectiveness of recall systems for improving influenza vaccination coverage in children with oncohematological malignancies. Hum. Vaccin. 6, 194–197 (2010).
- Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13–17 years--United States, 2011. MMWR Morb. Mortal Wkly. Rep. 61, 671–677 (2012). Erratum in: MMWR Morb Mortal Wkly Rep. 61, 844 (2012).
- Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children – use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59(RR–11), 1–18 (2010).
- Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal Wkly. Rep. 61, 816–819 (2012).
- Principi N, Esposito S. Use of the 13-valent pneumococcal conjugate vaccine in infants and young children. Expert Opin. Biol. Ther. 12, 641–648 (2012).
- Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 1, CD000422 (2013).